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Abstract
Aims/hypothesis Elevated hepatic lipase (HL, also known
as LIPC) expression is a key factor in the development of
the atherogenic lipid profile in type 2 diabetes and insulin
resistance. Recently, genetic screens revealed a possible
association of type 2 diabetes and familial combined hyper-
lipidaemia with the USF1 gene. Therefore, we investigated
the role of upstream stimulatory factors (USFs) in the regula-
tion of HL.
Methods Levels of USF1, USF2 and HL were measured in
HepG2 cells cultured in normal- or high-glucose medium
(4.5 and 22.5 mmol/l, respectively) and in livers of
streptozotocin-treated rats.
Results Nuclear extracts of cells cultured in high glucose
contained 2.5±0.5-fold more USF1 and 1.4±0.2-fold more
USF2 protein than cells cultured in normal glucose (mean±
SD, n=3). This coincided with higher DNA binding of
nuclear proteins to the USF consensus DNA binding site.
Secretion of HL (2.9±0.5-fold), abundance of HL mRNA
(1.5±0.2-fold) and HL (–685/+13) promoter activity (1.8±
0.3-fold) increased in parallel. In chromatin immunopre-
cipitation assays, the proximal HL promoter region was
immunoprecipitated with anti-USF1 and anti-USF2 anti-
bodies. Co-transfection with USF1 or USF2 cDNA stimu-
lated HL promoter activity 6- to 16-fold. USF and glucose
responsiveness were significantly reduced by removal of
the −310E-box from the HL promoter. Silencing of the
USF1 gene by RNA interference reduced glucose respon-
siveness of the HL (−685/+13) promoter region by 50%.
The hyperglycaemia in streptozotocin-treated rats was
associated with similar increases in USF abundance in rat
liver nuclei, but not with increased binding of USF to the
rat Hl promoter region.
Conclusions/interpretation Glucose increases HL expres-
sion in HepG2 cells via elevation of USF1 and USF2. This
mechanism may contribute to the development of the
dyslipidaemia that is typical of type 2 diabetes.
Keywords Glucose . Hepatic lipase . Human hepatoma
cells .Metabolic syndrome . Transcription . Upstream
stimulatory factor
Abbreviations
AdML adenovirus major late promoter
Apo apolipoprotein
ChIP chromatin immunoprecipitation
ChREBP carbohydrate responsive element binding
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pUSF upstream stimulatory factor expression plasmid
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Introduction
Morbidity and mortality rates in patients with type 2
diabetes are largely dominated by the occurrence of athe-
rosclerotic cardiovascular disease [1]. The insulin-resistant
state that precedes the development of type 2 diabetes is also
associated with increased risk of cardiovascular disease
[2–4]. The dyslipidaemia that typically occurs in insulin-
resistant states such as central obesity, metabolic syndrome,
type 2 diabetes and familial combined hyperlipidaemia
(FCHL) [5, 6] is an important contributor to the development
of coronary artery disease and consists of hypertriacylglycer-
olaemia, low HDL-cholesterol and a preponderance of small,
dense LDL particles [3, 7]. Hepatic lipase (HL) plays a key
role in lipoprotein metabolism and in the remodelling of
HDL and LDL [8]. HL is a lipolytic enzyme that mediates
the formation of small dense LDL and the reduction of HDL-
cholesterol levels [8, 9]. Elevated HL levels are associated
with dyslipidaemia in metabolic syndrome and type 2
diabetes [9, 10], and the HL gene (also known as LIPC) is
associated with the lipoprotein abnormalities in FCHL [11].
HL expression is increased in type 2 diabetes [12, 13].
Although insulin-resistant states are commonly associated
with hyperinsulinism, a direct stimulating effect of insulin
on HL expression has not been unequivocally established
[10]. Instead, acute hyperinsulinaemia actually reduces HL
expression [14]. HL activity correlates with parameters of
insulin resistance in non-diabetic men [15, 16] and in
FCHL [16]. In an animal model, HL levels were increased
upon induction of insulin resistance, which could be
partially reversed by treatment with an insulin sensitiser
[17]. It is likely therefore that some aspect of insulin
resistance induces the increase in HL expression. HL activity
is strongly increased with omental fat mass, a parameter of
visceral obesity with increased risk of developing type 2
diabetes [18]. This suggests that HL expression may increase
with fatty acid supply to the liver. Indeed, in vitro HL
expression is increased by fatty acids [19, 20]. Recently,
transcription of the HL gene in HepG2 cells was shown to be
increased by glucose [21]. Hence, HL levels may be elevated
in insulin-resistant states as a consequence of hyperglycae-
mia and increased fatty acid delivery to the liver.
We recently found that transcription of the HL gene in
HepG2 cells was stimulated by the upstream stimulatory
factor (USF)1 [20, 22], a transcription factor that controls
expression of several genes involved in glucose and lipid
homeostasis [23]. USF1 binds as a homodimer or as a
heterodimer with highly homologous USF2, to E-box
motifs in gene regulatory sequences. In the liver, expression
of the genes coding for glucokinase, fatty acid synthase,
apolipoprotein (Apo)A-II, ApoA-V, ApoC-III and ApoE is
upregulated by USF [24–29]. In liver as well as in other
tissues, USFs play an important role in the regulation of
genes by insulin [24–26] or glucose [30–34]. Interestingly,
the USF1 gene on chromosome 1q21 has been linked with
type 2 diabetes [35], FCHL [36, 37] and both cardiovas-
cular disease and all-cause mortality among women [38].
Allelic variants of USF1 may confer susceptibility to core
features of the metabolic syndrome, such as glucose
intolerance and dyslipidaemia [36, 39, 40].
USF1 and USF2 are ubiquitously expressed. It is unclear
how they convey glucose or insulin responsiveness to
susceptible target genes. In USF1 a number of polymorphisms
have been reported [36, 38, 40], some of which are associated
with unfavourable results in oral glucose and fat tolerance
tests [41], increased adipocyte lipolysis [42] and decreased
expression of USF target genes in fat biopsies [40]. In non-
hepatic cells, glucose has been shown to increase nuclear
expression of either USF1 or USF2 [31–34]. We hypothesised
therefore that expression of USF1 or USF2 itself is subject to
regulation by glucose. In this study we tested: (1) whether
glucose affects nuclear expression of USF proteins in
hepatoma cells; and (2) whether this could explain the
upregulation of HL expression seen in the high-glucose states.
Methods
Cell culture and hepatic lipase secretion HepG2 cells were
cultured in DMEM/10% FCS (vol./vol.) [43], containing
either high or normal glucose (all from Gibco BRL, Breda,
the Netherlands). Glucose was determined using a sensor
(AccuTrend; Roche, Almere, the Netherlands) and was 22.5
and 4.5 mmol/l in fresh high and normal glucose medium,
respectively. Glucose in cell-conditioned media was mea-
sured daily. The medium was refreshed every second day or
daily if medium glucose had dropped below 1 mmol/l,
which occurred occasionally and only when cell cultures
were near-confluent. The cultures were split every 5 days.
To avoid complications due to acute osmotic effects, cells
were maintained at either high or low glucose medium for
at least four passages before the start of the experiments.
Hepatic lipase secretion was determined as described
[43]. HL activity was expressed as nmol of NEFA released
per min from triolein.
RNA analysis Total RNA was isolated from a confluent
T25 flask of HepG2 cells using the TRIzol reagent
(Invitrogen, Leek, the Netherlands). The amount of HL
mRNA was quantified by reverse-transcription followed by
quantitative real-time PCR (qPCR) as described previously
[43]. HL mRNA levels were normalised to acidic ribosomal
phosphoprotein PO (36B4) mRNA.
Determination of USF1 and USF2 expression Nuclear
extracts were prepared from the cells of one confluent
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T25 culture flask and the proteins were analysed by
immunoblotting as described previously [43]. USF1 and
USF2 protein were detected by a 1:500 dilution of rabbit
anti-human USF1 and anti-human USF2 (both C20; Santa-
Cruz Biotechnology, Santa Cruz, CA, USA), respectively.
B23 protein was detected by 1:10,000 dilution of mouse
monoclonal anti-B23. Bound rabbit and mouse antibodies
were detected by a 1:5,000 dilution of the respective
horseradish peroxidase-coupled secondary antibodies.
Human USF1 and USF2 proteins were synthesised in vitro
using the TnT reticulocyte lysate system (Promega, Leiden,
the Netherlands) according to the manufacturer’s instructions,
with USF1 cDNA and USF2 cDNA in pcDNA3 (pUSF1 and
pUSF2) as expression vectors, respectively. pUSF1 was
obtained from B. Staels (Pasteur Institute, Lille, France).
The entire coding sequence of USF2 cDNAwas generated by
RT-PCR on total HepG2 RNA using 5′-gcgaattCCATGGA
CATGCTGGAC-3′ as forward primer and 5′-gctctaga
GCGTGGTGGTGGCGG-3′ as reverse primer. The extra
EcoRI and XbaI restriction sites (sequences underlined) were
used for cloning into pcDNA3. The insert was verified by
DNA sequencing (BaseClear, Leiden, the Netherlands).
Gelshift assays Gelshift assays using 32P-labelled probes
were performed as described previously [22]. Assays using
biotinylated probes were performed with a kit (LightShift
Chemiluminescent EMSA Kit; Pierce, Rockford, IL, USA).
In supershift assays, the nuclear extract protein was pre-
incubated for 30 min on ice with 1 µl of anti-USF1 (C-20),
anti-USF2 (C-20) or anti-sterol regulatory element-binding
protein (SREBP)2 (N-19; Santa-Cruz).
Measurement of HL promoter activity Transcriptional
activity of the human HL (–685/+13) promoter fragment
was determined by transient transfection of the HepG2 cells
with the HL–685 luciferase vector as described previously
[20], except that the medium was also refreshed at 24 h post
transfection. Co-transfection with pRL-TK (Promega) was
used as internal control and luciferase activity data were
normalised on the basis of Renilla activity. Each transfec-
tion assay was performed in quadruplicate.
From the HL(–685/+13) promoter construct in pGL3, the
5′-deleted HL–305 promoter construct was prepared by
PCR using appropriate oligonucleotide primers. In the HL–
685 construct, the –310 E-box CACGTG was scrambled by
PCR-directed mutagenesis into GCTAGC (Em). Similarly,
the –514 E-box CACGGG (–514C) was changed into
CATGGG (–514T). Mutations were verified by automated
sequencing (BaseClear).
RNA interference analysis RNA silencing of USF1 and
USF2 was performed by transient transfection with pSi-
lencer 3.1-H1 hygro expression vector (Ambion, Austin
TX, USA), which generates short-hairpin RNA (shRNA)
molecules. The sequences of the shRNA molecules directed
against USF1 and USF2 partially overlapped with the
targeting sites used by McMurray and McCance [44]. The
sequences of the shRNA molecules were: for USF1 5′-
GGTGGGATTCTATCCAAAGCTTCAAGAGAGCTTTG
GATAGAATCCCACCTTTTTT-3′; and for USF2 5′-GGA
GATACTACGGCTGTGTCCAAGCTTGGACAC
AGCCGTAGTATCTCCTTTTT-3′. As controls, parallel
transfections were performed with empty pSilencer vector
or with pSilencer constructs targeted against two non-related
genes (AQP3 and AQP7).
Chromatin immunoprecipitation assays Chromatin immu-
noprecipitation (ChIP) assays were performed as described
previously [43] using anti-USF1 or anti-USF2 antibodies
(Santa Cruz). The immunoprecipitated DNA was subjected
to qPCR; amplified regions of the human HL gene were
480/–352 (primers 5′-CACAAGCATCACCAATTTCAC-3′
and 5′-GCTGGCTCAGGAAAGTGG-3′) and –6071/–5986
(primers 5′-CTTGGGATTTGCTTGCTTTATC-3′ and 5′-
ATTTGATGACCTGAGAATGACC-3′). Alternatively, the
PCR products were resolved by 3% (wt/wt) agarose gel
electrophoresis and visualised by ethidium bromide staining.
Livers from diabetic rats Female Wistar rats weighing 250
to 350 g were housed in a reversed light-cycle room and
had free access to water and standard rodent chow. Animal
experiments were carried out according to the regulations of
the local Animal Care and Use Committee. Animals were
made diabetic by a single intraperitoneal injection of
55 mg/kg of streptozotocin (Sigma, St Louis, IL, USA) in
100 mmol/l sodium citrate (pH 4.5) [45]. Control animals
were injected with vehicle only. At 7 weeks, rats were
killed by an isoflurane overdose. Glucose was determined
in full blood samples. Liver portions were quickly removed
into liquid nitrogen and stored at –80°C until further
analysis. For immunoblotting assays, nuclear extracts were
prepared from frozen 100 mg liver aliquots. Of each
extract, 50 µg protein was tested for USF1 and USF2 as
described above and 1 µg for histone H3 using rabbit anti-
H3 antibody (1:2500; Abcam, Cambridge, UK).
For ChIP assays, 100 mg liver aliquots were powdered
in liquid nitrogen and immediately thawed in 1 ml of 1%
(wt/wt) formaldehyde in PBS. After 10 min incubation at
37°C, the homogenate was diluted once in 2% (wt/wt) SDS,
20 mmol/l EDTA, 100 mmol/l Tris–HCl (pH 8.0). ChIP
assays were performed as described for HepG2 cells [43].
Amplified regions of the rat Hl gene were –392/–282
(primers 5′-GGGGCTTTTACCTCTCTTTGGG-3′ and 5′-
TGACCTCTGTATTGTTGCCTGTG-3′) and –7328/–7214
(primers 5′-CACAGCAACACGAGCCTCAG-3′ and 5′-
TGCAGTGTAGAATTTGTGGCATACC-3′). For determi-
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nation of HL activity, frozen 100 mg liver aliquots were
homogenised in 2 ml heparin containing PBS on ice using a
homogeniser (UltraTurrax T25; IKA, Staufen, Germany).
HL activity was determined in the homogenate [43] and
was completely inhibited by preincubation with excess anti-
rat HL antiserum.
Statistics All data are expressed as means±SD. Statistical
analyses were performed using Student’s t test. Statistical
significance was defined as p<0.05.
Results
Glucose increases both HL expression and nuclear accu-
mulation of USF1 and USF2 HepG2 cells that had been
cultured to confluence at 22.5 mmol/l glucose were
incubated for an additional 8 h in medium containing
normal (4.5 mmol/l), intermediate (9 mmol/l) or high
(22.5 mmol/l) glucose. Secretion of HL increased with
increasing glucose concentration (Fig. 1a). In the high-
glucose medium, HL secretion was 2.9±0.5-fold higher
than in the normal-glucose medium. After 8 h of incubation
under these conditions (confluent wells and reduced
medium volume), glucose was completely depleted from
the normal-glucose medium. In the high-glucose medium,
glucose was reduced to 13.0±1.9 mmol/l (n=3). In medium
with intermediate glucose concentration, extracellular glu-
cose decreased from 9 to 1.6±0.3 mmol/l (n=3). HL
secretion was also intermediate between the normal- and
high-glucose cells. In further experiments, cells were
incubated with higher volumes of medium per well, with
the medium being refreshed daily to keep extracellular
glucose above 1 mmol/l throughout the incubation. Under
these conditions, the abundance of HL mRNA, as deter-
mined by qPCR, in high-glucose cells was 1.5±0.2-fold
higher than in parallel normal-glucose cells (p=0.028, n=
3). To test the effect of glucose on HL transcription, cells
were transiently transfected with the HL–685 luciferase
promoter–reporter construct. Luciferase activity in the high-
glucose cells was 1.8±0.3-fold higher than in the normal-
glucose cells (p=0.036; n=3). This suggests that glucose
dose-dependently increases HL secretion, largely by affect-
ing transcription of the HL gene.
The amount of USF1 protein in nuclear extracts prepared
from high-glucose cells was 2.5±0.5-fold higher than that in
the normal-glucose cells medium (n=3, p=0.042) (Fig. 1b).
USF2 was slightly, but significantly, higher in the high-
glucose cells (1.4±0.2-fold, n=3, p=0.010). In contrast, the
amount of B23 protein was similar in both nuclear extracts.
Glucose increases DNA binding activity of USF In gelshift
assays with HepG2 nuclear extracts and adenovirus major
late promoter (AdML), the USF consensus-binding site, a
similar shift was produced with high- and normal-glucose
cells (Fig. 2a). With the high-glucose cells, markedly more
probe was shifted than with the normal-glucose cells. The
shifted band co-migrated with in-vitro synthesised USF1
and USF2 proteins run in parallel. In supershift assays, the
band was partially shifted to higher positions in the gel after
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Fig. 1 High glucose increases HL secretion and nuclear accumulation of
USF proteins. a HepG2 cells were incubated for 8 h in medium
containing heparin and the indicated amounts of glucose. At the end of
incubation, HL activity was determined in the cell-free media. Data are
mean±SD for three to five independent experiments. b HepG2 cells were
cultured with 4.5 (normal glucose [NG]) or 22.5 mmol/l (high glucose
[HG]) glucose. At confluence, nuclear extracts were prepared and the
presence of USF1 and USF2 protein was detected by immunoblotting (in
duplicate). B23 protein served as internal control. TnT 1 and 2 are 0.5
and 1.0 μl respectively of in vitro transcribed and translated USF, and
served as positive controls. Molecular masses are in kDa. c The data (b)
were quantified by densitometry, the two parallels averaged and data
expressed as percentage of NG controls. Data are mean±SD for three to
four independent experiments. *p<0.05, **p<0.01
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preincubation of the nuclear extracts with antibodies against
USF1 or USF2 (Fig. 2b), but not with antibodies against
SREBP2. A complete supershift was induced by preincu-
bation with anti-USF1 and anti-USF2 combined. These data
indicate that glucose increases the amount and DNA
binding activity of USF proteins in HepG2 cell nuclei and
suggest that the USF proteins induced by glucose are active
in DNA binding.
Glucose increases USF1 and USF2 binding to the HL
promoter in chromatin The proximal HL promoter region
co-immunoprecipitated with both anti-USF1 and anti-USF2
(Fig. 3a). Significantly more PCR product was generated
with DNA immunoprecipitated from high-glucose than
from normal-glucose cells using primers specific for the
proximal HL promoter region (–480/–352) (Fig. 3b). In
contrast, the amount of PCR product generated with distal
HL gene-specific primers (–6071/–5965) was negligible
and not affected by glucose conditioning. Hence, both
USF1 and USF2 are bound to the proximal HL promoter
region in the HepG2 nuclei in situ and binding is higher in
high-glucose than in normal-glucose cells.
Glucose-induced increase of HL promoter activity is
reduced by removal of potential USF binding sites Co-
transfection of HL–685 with 10 and 24 ng of pUSF1
increased luciferase activity approximately 6- and 16-fold,
respectively (Fig. 4b,c). In this HL promoter fragment,
E-boxes that potentially bind USF are present around
positions –514 and –310. We were not able to show
binding of endogenous USFs to these sites in gelshift
assays with HepG2 nuclear extracts, in agreement with the
low binding affinity compared with the AdML consensus
site [22]. However, purified USFs have been shown to bind
to the –514 region of the HL promoter [22], and Fig. 4d
demonstrates binding of USF1 and USF2 to the –310
region in nuclear extracts of HepG2 cells transiently
transfected with the respective expression plasmids. Muta-
tion of the –514 E-box from CACGGG (–514C) into the
allelic variant CATGGG (–514T) reduced responsiveness of
the HL–685 construct to USF1 and USF2, but this
reduction did not reach statistical significance (Fig. 4b).
Scrambling of the –310 E-box sequence from CACGTG
(–310E) to GCTAGC (–310Em) reduced responsiveness to
USF1 and USF2 to approximately 50% (p=0.006 and p=
0.001, respectively; n=4) (Fig. 4c). This suggests that
USF1 and USF2 upregulate HL promoter activity in part
through binding at the –310E-box.
Compared with HL–685, the HL–305 construct lacks
both potential USF binding sites at –514 and –310. Both
reporter constructs were tested in parallel for promoter
activity. Whereas in this series of experiments the activity of
HL–685 was 2.4±0.6-fold higher in the high-glucose than in
the normal-glucose cells, this value was only 1.6±0.3-fold
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Fig. 2 Glucose increases E-box DNA binding activity in HepG2
nuclei. a Gelshift and (b) supershift assays were performed using 32P-
labelled AdML oligonucleotides containing consensus USF binding
sites and nuclear extracts (2.5 µg protein) from HepG2 cells that had
grown to confluence in normal glucose (NG) or high glucose (HG). a
Nuclear extracts (NE) from four different incubations were run in
parallel and with TnT reticulolysate extracts that had been incubated
with pUSF1 or pUSF2. b The nuclear extracts were pre-incubated
with the antibody indicated prior to the probe. Arrows indicate the
positions of the shifted and supershifted bands
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Fig. 3 Chromatin immunoprecipitation assays with HepG2 cells.
Chromatin was immunoprecipitated from HepG2 cells with anti-USF1
or anti-USF2 and the DNA was analysed by PCR using HL-specific
primers. a Part of the proximal HL promoter region (−480/−352) was
amplified (30 cycles at 30 s 95°C, 30 s 55°C and 45 s 72°C) using
4 µl immunoprecipitate, and PCR products were analysed by agarose
gel electrophoresis and ethidium bromide staining. As positive and
negative controls, 1% input DNA and no-antibody immunoprecipita-
tion (Mock) were included, respectively. W, PCR water control; M,
the 123 bp DNA ladder from Roche. b DNA immunoprecipitated with
the indicated antibody from normal-glucose (black and grey bars) and
high-glucose (white and stippled bars) cells was analysed by qPCR,
amplifying either the −480/−352 (black and white bars) or −6071/
−5965 (grey and stippled bars) regions of the HL gene. Data are
mean±SD of three independent experiments. a,bStatistically significant
difference from mock and normal glucose, respectively
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with the shorter construct (p=0.037; n=5) (Fig. 4e). Hence,
the E-boxes in the HL promoter are also important for full
glucose responsiveness.
Glucose-induced increase of HL promoter activity is
reduced by silencing of USF1 Transfection of HepG2 cells
with pSilencer plasmids that code for shRNA directed
against USF1 and USF2 markedly reduced the amount of
USF1 and USF2 protein in nuclear extracts, respectively
(Fig. 5a). In normal-glucose cells, HL promoter activity was
slightly but significantly reduced by co-transfection with
short-hairpin USF (shUSF)1 and shUSF2 (Fig. 5b). In the
high-glucose cells, the HL promoter activity was reduced
to approximately 50% of parallel controls, with upregula-
tion by high-glucose almost completely prevented by co-
transfection with shUSF1. Similar trends were observed
with shUSF2, but the effects did not reach statistical
significance. shRNA constructs directed against non-related
AQP3 or AQP7 did not affect HL promoter activity in the
high-glucose cells (Fig. 5c).
Hl expression in livers of streptozotocin-treated rats To test
whether chronically elevated glucose affects Usf and Hl
expression in vivo, we used livers of streptozotocin-treated
rats. Whole-blood glucose concentration in streptozotocin-
treated rats was 23.9±1.2 mmol/l compared with 5.9±
0.5 mmol/l in control rats (p<0.05; n=3). In livers of the
treated rats, nuclear expression of USF1 was 2.1-fold (p<
0.05; n=3) higher and that of USF2 was 1.4-fold (p<0.05;
n=3) higher than in parallel controls (Fig. 6a). In ChIP
assays, the proximal region of the rat Hl gene (–392/–282)
was immunoprecipitated with anti-USF1 and anti-USF2, but
not a distal region of the Hl gene (–7329/–7214), indicating
that USF proteins are specifically bound to the proximal
promoter region of Hl in rat liver (Fig. 6b). Binding of
USF proteins to the upstream region of Hl was not
significantly affected by high glucose levels, as similar
amounts of DNA were immunoprecipitated from livers of
streptozotocin-treated and control rats. HL activity in liver
homogenates amounted to 4.3±0.4 and 10.6±2.8 nmol
min−1 (mg protein) −1 in streptozotocin-treated and control
rats, respectively (p<0.05; n=3).
Discussion
Our study shows that HepG2 cells contain more USF1 and
USF2 protein in their nuclei under high- than under low-
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responsiveness to USF1 and glucose. a Schematic representation of
the HL (–685/ + 13) promoter fragment, indicating the position of two
potential USF-binding E-box motifs. The role of these E-boxes was
tested either by mutating them (b, c) or by removing both E-boxes by
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with USF1 and USF2 in transient co-transfection assays. High-glucose
HepG2 cells were co-transfected with 24 ng (b) or 10 ng (c) of pUSF1
(grey bars) and pUSF2 (black bars). Luciferase activities were
expressed relative to the activities measured in cells co-transfected
with empty pcDNA3 vector (control, white bars). a,bStatistically
significant difference from control cells and from the wild-type
construct, respectively. d A gelshift of biotinylated −300/−320 region
of the HL gene and nuclear extracts of HepG2 cells that were
transiently transfected with 100 ng of pUSF1 or pUSF2 or with empty
vector. Arrows, position of the shifted bands; *, non-specific bands. e
The glucose responsiveness of HL–685 compared with HL-305.
HepG2 cells grown in normal (white bars) or high (hatched bars)
glucose were transiently transfected with both promoter constructs and
the luciferase activity was determined. Activities in the normal-
glucose cells were set at 1.0. Activities in the high-glucose cells were
expressed as fold increase relative to normal-glucose cells. Data are
mean±SD of four to five independent experiments. a,bStatistically
significant difference from normal-glucose cells and from the full-
length construct, respectively
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glucose conditions. As extracellular glucose concentrations
in our experiments frequently reached very low levels, it
could be argued that USF proteins disappear from the
nuclei in low-glucose conditions. However, we favour the
interpretation that high glucose induces the nuclear accu-
mulation of USF proteins, as increased expression of both
USF proteins was also observed in livers of hyperglycae-
mic, streptozotocin-treated rats. In HepG2 cells, this was
paralleled by increased binding of USFs to the HL promoter
region and a parallel increase in HL expression. The human
HL gene is a potential target for USF, as (1) USF proteins
were bound to the proximal promoter region in HepG2 cells
(Fig. 3), (2) this region contains functionally important E-
boxes and (3) HL promoter activity was dose-dependently
upregulated by overexpression of USF1 or USF2 (Fig. 4).
Silencing of USF1 by RNA interference strongly reduced
the glucose-induced upregulation of HL promoter activity
(Fig. 5). Therefore, the USF proteins that accumulate in the
nuclei of HepG2 cells are important in mediating the
glucose-induced increase in HL expression. Glucose re-
sponsiveness of the HL promoter was not completely lost
upon deletion of the E-boxes. Hence, the glucose-induced
upregulation of HL promoter activity may be mediated by
USFs via additional, non-E box elements. Co-transfection
with pUSF1 and pUSF2 also increased transcription of
proximal HL promoter constructs through binding of USFs
to the transcription initiation site (D. van Deursen, H.
Jansen and A.J.M. Verhoeven, unpublished results). In rat
liver chromatin, USF1 and USF2 protein apparently bind to
the proximal Hl promoter region at non-E box elements, as
this region of the rat Hl gene lacks canonical E-boxes.
Alternatively, glucose may activate the HL promoter
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Fig. 5 Silencing USF1 reduces glucose-induced upregulation of HL
promoter activity. HepG2 cells were co-transfected with HL–685 and
100 ng of the indicated shRNA construct in pSilencer. a Effect of
shUSF1 on endogenous USF1 protein and of shUSF2 on endogenous
USF2 protein in nuclear extracts as indicated. Nuclear protein (25 μg)
was run in parallel with in vitro synthesised USF protein (TnT). *,
cross-reacting band. b HL–685 promoter activity was determined in
cells co-transfected with 100 ng shUSF1, shUSF2 or pSilencer.
Luciferase data were expressed as fold stimulation relative to the
activity with pSilencer measured in normal-glucose cells. Data are
mean±SD of five independent experiments. c The effect of the
shUSF1 construct was compared with shRNA constructs directed
against AQP3 and AQP7. Cells were incubated in high-glucose
medium. Data are means±SD of five parallel incubations. a,bStatisti-
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Fig. 6 Effect of chronically elevated blood glucose on USF
expression and ChIP in rat liver. a Expression of USF1 and USF2
was determined in liver nuclear extracts of three control rats (Con) and
three streptozotocin-treated rats (Diab), using histon H3 as loading
control. The normalised signal densities (arbitrary units) were 19.0±
2.8 vs 9.0±0.9 for USF1 and 72.7±11.5 vs 51.0±5.7 for USF2 in
treated vs control livers, respectively (n=3). Molecular masses are
indicated in kDa. b ChIP assays were performed with chromatin
isolated from livers of control (white bars) and streptozotocin-treated
(black bars) rats and with anti-USF1, anti-USF2 or no (Mock)
antibodies. Immunoprecipitated DNA was analysed by qPCR using
rat Hl-specific primers targeted at the indicated regions. Data are mean
±SD of three independent experiments. aStatistically significant
difference from mock
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through additional mechanisms that are independent of
USFs. Recently, carbohydrate responsive element binding
protein (ChREBP) was identified as a major glucose-
responsive transcription factor in liver cells; its consensus
DNA binding site, however, consists of two E-boxes
separated by 5 bp [46]. Using MatInspector (matrix
similarity > 0.82) [47], we found such a potential binding
site within 2 kb of the proximal USF1 and USF2 but not of
the HL promoter region. Moreover, fatty acids decrease
expression of glucose-responsive gene through decrease of
ChREBP activity [48], whereas fatty acids increased HL
[19, 20] and nuclear USF expression (D. van Deursen and
A. J. M. Verhoeven, unpublished observations) in HepG2
cells. A major role for ChREBP in mediating glucose-
responsiveness to HL therefore appears unlikely.
In contrast to HepG2 cells, the accumulation of USF1
and USF2 in liver nuclei of streptozotocin-treated rats was
not accompanied by increased binding of USFs to the
proximal Hl promoter region. In addition, Hl expression
was reduced in this in vivo model. Apparently, increased
abundance of USF proteins is not the only factor that
regulates USF binding activity and HL expression. In the in
vivo model, liver cells are not only chronically exposed to
hyperglycaemia and low insulin, but also to many other
variables not mimicked in our in vitro model, e.g. elevated
fatty acid levels, glucocorticoids and glucagon. Our
preliminary data show that addition of 1 mmol/l BSA-
bound oleate to the high-glucose medium further increased
USF1 expression, HL promoter activity and secretion of HL
in HepG2 cells. In contrast, glucocorticoids and glucagon
lower Hl expression in rat hepatocytes [49, 50], possibly
through mechanisms that override the positive effect of
increased nuclear levels of USFs. One possibility is that
USFs become phosphorylated, thereby affecting their DNA
binding activity [23, 26]. Whether increased nuclear
expression of USF protein leads to increased USF binding
to the proximal HL promoter and subsequently to upregu-
lation of HL expression apparently depends on the species
studied or on the prevailing metabolic or hormonal status.
Alternatively, the hyperglycaemia-induced, USF-mediated
upregulation of HL expression may be restricted to human
hepatoma cells.
USF1 and USF2 are ubiquitously expressed. In various
non-hepatoma cells, glucose has been shown to increase
either nuclear USF1 or USF2 or both [32–34]. In HepG2
cells, glucose increases predominantly nuclear USF1, and
silencing of USF1 but not USF2 abolished the increase in
HL promoter activity. In mouse liver, glucose responsive-
ness is mainly signalled through the USF1–USF2 hetero-
dimer, but the homodimers are also transcriptionally active
[30]. Hence, upregulation of either USF1 or USF2 may
affect expression of target genes. The relative importance of
USF1 and USF2 overproduction may depend on which of
the two proteins is limiting in the cell type used. Taken
together, our data suggest that the nuclear accumulation of
USF1 and USF2 signals glucose responsiveness to the HL
gene and probably to other USF target genes. The
mechanism that leads to accumulation of USF1 and USF2
by glucose is presently unknown. In adipocytes, glucose has
to be metabolised in the glycolytic pathway beyond glucose-
6-phosphate to triose phosphates [31]. Further research is
required to show whether this also holds for liver cells.
USF1 and USF2 are involved in the coordinate regula-
tion of glucose and lipid metabolism [23, 40], in which the
liver plays a central role. The finding of increased nuclear
expression of USF proteins may therefore bear relevance to
the causes of insulin resistance and type 2 diabetes. The
associated dyslipidaemia (low HDL, high triacylglycerol,
increased small dense LDL) may result from the increased
transactivation by USFs, not only of HL, but also of other
HDL- and triacylglycerol-related genes [26–29, 31]. In-
creased USF1 transactivation of its target genes has been
suggested to explain the development of the metabolic
syndrome [35, 39], the dyslipidaemia associated with
FCHL [36, 40] and the development of diabetic complica-
tions [32, 34]. Metabolic syndrome, type 2 diabetes and
FCHL have all been linked to the USF1 gene [35–37]. A
number of risk alleles of USF1 have been identified, which
all represent variants of the non-coding sequence [36, 38,
41]. It is not clear how non-coding polymorphisms in USF1
may contribute to these metabolic disorders. The polymor-
phism in intron 7 of USF1 [36] has been shown to affect
binding of nuclear proteins to this region [38], suggesting
that this polymorphism affects transcriptional or post-
transcriptional regulation of USF1 expression. Possibly,
these polymorphisms interfere with the glucose-mediated
nuclear accumulation of USF1 in the liver. Further studies
are required to elucidate the mechanism by which glucose
affects USF1 and USF2 expression and how genetic
variants of USF1 may alter responsiveness to glucose.
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